Progress in lung cancer detection through AI highlights the potential for similar advancements in pancreatic cancer, though a comprehensive dataset is still needed. With only 4% of pancreatic cancer patients participating in clinical trials, there's a pressing need for innovation. The adaptive platform trial designed by Diane and her team allows for a more flexible approach, enabling patients to switch therapies and increasing the chances of FDA approval for multiple treatments.
